Oppenheimer Maintains Outperform on Kymera Therapeutics, Raises Price Target to $56
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jeff Jones has maintained an 'Outperform' rating on Kymera Therapeutics and raised the price target from $52 to $56.
September 27, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has reaffirmed its 'Outperform' rating for Kymera Therapeutics and increased the price target to $56, indicating confidence in the company's future performance.
The increase in price target from $52 to $56 by Oppenheimer suggests a positive outlook on Kymera Therapeutics' future performance. The 'Outperform' rating indicates that the analyst expects the stock to perform better than the market average, which could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100